Form 8-K - Current report:
SEC Accession No. 0001193125-24-156050
Filing Date
2024-06-06
Accepted
2024-06-06 16:07:30
Documents
13
Period of Report
2024-06-06
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d844544d8k.htm   iXBRL 8-K 35109
  Complete submission text file 0001193125-24-156050.txt   153742

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amlx-20240606.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20240606_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20240606_pre.xml EX-101.PRE 10810
16 EXTRACTED XBRL INSTANCE DOCUMENT d844544d8k_htm.xml XML 3505
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 241025068
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)